
Axon Enterprise AXON
$ 402.6
2.54%
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
78.1 M |
Market Cap[1] |
$ 31.4 B |
EBITDA (LTM) |
$ 21.1 M |
P/E (LTM) |
322.29375 |
P/S (LTM) |
14.485882 |
EPS (LTM) |
1.6 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Royalty Pharma plc
RPRX
|
$ 62.15 | -0.16 % | $ 26.7 B | Nasdaq Global Select Market | ||
|
Seer
SEER
|
$ 2.03 | 2.53 % | $ 112 M | Nasdaq Global Select Market | ||
|
PDS Biotechnology Corporation
PDSB
|
$ 1.24 | 29.1 % | $ 57.5 M | Nasdaq Capital Market | ||
|
Zymeworks
ZYME
|
$ 28.12 | 4.48 % | $ 1.45 B | NYSE | ||
|
SIGA Technologies
SIGA
|
$ 3.12 | -0.95 % | $ 223 M | Nasdaq Global Select Market | ||
|
Nanobiotix S.A.
NBTX
|
$ 25.83 | 7.0 % | $ 1.24 T | Nasdaq Global Select Market | ||
|
22nd Century Group
XXII
|
$ 0.27 | 2.13 % | $ 49.7 K | NYSE American | ||
|
Syndax Pharmaceuticals
SNDX
|
$ 13.15 | -0.75 % | $ 1.14 B | Nasdaq Global Select Market | ||
|
Soligenix
SNGX
|
$ 0.35 | -1.27 % | $ 1.82 M | Nasdaq Capital Market | ||
|
Intellia Therapeutics
NTLA
|
$ 11.65 | -1.6 % | $ 1.26 B | Nasdaq Global Market,SPB | ||
|
Nuvation Bio
NUVB
|
$ 4.85 | 1.89 % | $ 1.66 B | NYSE | ||
|
Sarepta Therapeutics
SRPT
|
$ 18.56 | -3.18 % | $ 1.86 B | Nasdaq Global Select Market,SPB | ||
|
Processa Pharmaceuticals
PCSA
|
$ 1.76 | 1.73 % | $ 2.3 M | Nasdaq Global Select Market | ||
|
RedHill Biopharma Ltd.
RDHL
|
$ 0.46 | -10.31 % | $ 5.67 B | Nasdaq Global Market | ||
|
SELLAS Life Sciences Group
SLS
|
$ 12.14 | 1.34 % | $ 1.32 B | Nasdaq Capital Market | ||
|
Protara Therapeutics
TARA
|
$ 2.5 | -2.34 % | $ 107 M | Nasdaq Global Market | ||
|
Relay Therapeutics
RLAY
|
$ 18.41 | -0.22 % | $ 3.16 B | Nasdaq Global Market | ||
|
Pfizer
PFE
|
$ 29.85 | -0.95 % | $ 170 B | NYSE,SPB | ||
|
Supernus Pharmaceuticals
SUPN
|
$ 41.21 | -0.05 % | $ 2.33 B | Nasdaq Global Select Market,SPB | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
$ 19.93 | -0.75 % | $ 31.5 B | NYSE | ||
|
Revolution Medicines
RVMD
|
$ 194.28 | -1.15 % | $ 36.9 B | Nasdaq Global Select Market | ||
|
Rhythm Pharmaceuticals
RYTM
|
$ 88.62 | -1.75 % | $ 5.76 B | Nasdaq Global Market,SPB | ||
|
Prelude Therapeutics Incorporated
PRLD
|
$ 3.65 | 3.4 % | $ 281 M | Nasdaq Global Select Market | ||
|
Sana Biotechnology
SANA
|
$ 2.35 | -0.42 % | $ 595 M | Nasdaq Global Select Market | ||
|
Zai Lab Limited
ZLAB
|
$ 24.2 | -3.51 % | $ 26.5 B | Nasdaq Global Select Market | ||
|
Pulmatrix
PULM
|
$ 1.57 | 9.79 % | $ 5.73 B | Nasdaq Global Select Market | ||
|
Zentalis Pharmaceuticals
ZNTL
|
$ 2.36 | -1.26 % | $ 170 M | Nasdaq Global Market | ||
|
Zoetis
ZTS
|
$ 79.62 | -0.52 % | $ 35.3 B | NYSE,SPB | ||
|
Ultragenyx Pharmaceutical
RARE
|
$ 15.92 | -0.62 % | $ 1.57 B | Nasdaq Global Select Market,SPB | ||
|
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 1.87 | -3.61 % | $ 1.26 B | Nasdaq Capital Market | ||
|
Cleveland BioLabs, Inc.
CBLI
|
- | -7.31 % | $ 49 M | Nasdaq Capital Market | ||
|
AC Immune SA
ACIU
|
$ 2.47 | -0.8 % | $ 249 M | Nasdaq Global Market | ||
|
Five Prime Therapeutics, Inc.
FPRX
|
- | - | $ 1.77 B | Nasdaq Global Select Market | ||
|
Adagene
ADAG
|
$ 2.41 | -3.6 % | $ 142 M | Nasdaq Global Market | ||
|
Adial Pharmaceuticals
ADIL
|
$ 4.11 | 7.59 % | $ 2.75 M | Nasdaq Capital Market | ||
|
ADC Therapeutics SA
ADCT
|
$ 1.5 | -1.32 % | $ 191 M | NYSE | ||
|
ADMA Biologics
ADMA
|
$ 11.01 | -1.96 % | $ 2.62 B | Nasdaq Global Market | ||
|
Assembly Biosciences
ASMB
|
$ 20.46 | -3.45 % | $ 229 M | Nasdaq Global Select Market,SPB | ||
|
Allogene Therapeutics
ALLO
|
$ 1.33 | -0.38 % | $ 293 M | Nasdaq Global Select Market,SPB | ||
|
Amgen
AMGN
|
$ 438.34 | -0.14 % | $ 236 B | Nasdaq Global Select Market,SPB | ||
|
Ardelyx
ARDX
|
$ 3.13 | -2.49 % | $ 754 M | Nasdaq Global Market | ||
|
Armata Pharmaceuticals
ARMP
|
$ 3.06 | -4.38 % | $ 111 M | NYSE American | ||
|
Artelo Biosciences
ARTL
|
$ 2.56 | -2.29 % | $ 484 K | Nasdaq Global Select Market | ||
|
Biofrontera AG
BFRA
|
- | -8.24 % | $ 105 M | Nasdaq Capital Market | ||
|
Bicycle Therapeutics plc
BCYC
|
$ 3.57 | -0.83 % | $ 247 M | Nasdaq Global Select Market | ||
|
Catabasis Pharmaceuticals, Inc.
CATB
|
- | -6.97 % | $ 657 M | Nasdaq Global Market | ||
|
Beam Therapeutics
BEAM
|
$ 24.84 | -0.36 % | $ 2.46 B | Nasdaq Global Select Market | ||
|
China Biologic Products Holdings, Inc.
CBPO
|
- | 1.68 % | $ 4.65 B | Nasdaq Global Select Market | ||
|
Benitec Biopharma
BNTC
|
$ 8.5 | -5.97 % | $ 396 M | Nasdaq Capital Market | ||
|
BioNTech SE
BNTX
|
$ 91.29 | 0.13 % | $ 22.1 B | Nasdaq Global Select Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.